252 related articles for article (PubMed ID: 29023176)
1. Induction of Vogt-Koyanagi-Harada Disease by Interferon-Alpha and Ribavirin Treatment in Patients with Hepatitis C: A Case Report and Review of the Literature.
Duan J; Wang Y; Liu D; Ma J
Ocul Immunol Inflamm; 2019; 27(2):229-234. PubMed ID: 29023176
[TBL] [Abstract][Full Text] [Related]
2. Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.
Al-Muammar AM; Al-Mudhaiyan TM; Al Otaibi M; Abdo A; Abu El-Asrar AM
Int Ophthalmol; 2010 Oct; 30(5):611-3. PubMed ID: 20177954
[TBL] [Abstract][Full Text] [Related]
3. Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.
Lim JH; Lee YN; Kim YS; Kim SG; Jeong SW; Jang JY; Kim HS; Lee SH; Park TK
Korean J Hepatol; 2011 Mar; 17(1):61-5. PubMed ID: 21494079
[TBL] [Abstract][Full Text] [Related]
4. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.
Sylvestre DL; Disston AR; Bui DP
J Viral Hepat; 2003 Nov; 10(6):467-70. PubMed ID: 14633182
[TBL] [Abstract][Full Text] [Related]
5. Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.
Papastathopoulos K; Bouzas E; Naoum G; Vergados I; Tsiodras S
J Infect; 2006 Feb; 52(2):e59-61. PubMed ID: 15951019
[TBL] [Abstract][Full Text] [Related]
6. [Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].
Chebil A; Kort F; Bouraoui R; Youssef NB; El Matri L
J Fr Ophtalmol; 2010 Mar; 33(3):185-8. PubMed ID: 20172621
[TBL] [Abstract][Full Text] [Related]
7. Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C.
Touitou V; Bodaghi B; Cassoux N; Tran TH; Rao NA; Cacoub P; LeHoang P
Am J Ophthalmol; 2005 Nov; 140(5):949-52. PubMed ID: 16310490
[TBL] [Abstract][Full Text] [Related]
8. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.
Sene D; Touitou V; Bodaghi B; Saadoun D; Perlemuter G; Cassoux N; Piette JC; Hoang PL; Cacoub P
World J Gastroenterol; 2007 Jun; 13(22):3137-40. PubMed ID: 17589934
[TBL] [Abstract][Full Text] [Related]
9. A case of probable Vogt-Koyanagi-Harada disease in a 3-year-old girl.
Katsuyama A; Kusuhara S; Awano H; Nagase H; Matsumiya W; Nakamura M
BMC Ophthalmol; 2019 Aug; 19(1):179. PubMed ID: 31409322
[TBL] [Abstract][Full Text] [Related]
10. Vogt-Koyanagi-Harada syndrome in a case of multiple sclerosis.
Montero JA; Sanchis ME; Fernandez-Munoz M
J Neuroophthalmol; 2007 Mar; 27(1):36-40. PubMed ID: 17414871
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy.
Takayama K; Obata H; Takeuchi M
Ocul Immunol Inflamm; 2020 Apr; 28(3):509-512. PubMed ID: 31268769
[No Abstract] [Full Text] [Related]
12. Interferon-alpha2a and Vogt-Koyanagi-Harada disease: a double-edged sword?
Touitou V; Sene D; Fardeau C; Boutin TH; Duhaut P; Piette JC; LeHoang P; Cacoub P; Bodaghi B
Int Ophthalmol; 2007; 27(2-3):211-5. PubMed ID: 17318324
[TBL] [Abstract][Full Text] [Related]
13. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E
Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260
[TBL] [Abstract][Full Text] [Related]
14. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.
Kasahara A; Hiraide A; Tomita N; Iwahashi H; Imagawa A; Ohguro N; Yamamoto S; Mita E; Hayashi N
J Gastroenterol; 2004 Nov; 39(11):1106-9. PubMed ID: 15580406
[TBL] [Abstract][Full Text] [Related]
15. The Role of Widefield Optical Coherence Tomography Angiography in the Diagnosis and Management of Acute Vogt-Koyanagi-Harada Disease.
Ding X; Shu Q; Bai X; Chang Q; Xu G; Chen L
Ocul Immunol Inflamm; 2024 May; 32(4):391-401. PubMed ID: 36856749
[TBL] [Abstract][Full Text] [Related]
16. Multispectral image analysis in Vogt-Koyanagi-Harada disease.
Huang G; Peng J; Ye Z; Kijlstra A; Zhang D; Yang P
Acta Ophthalmol; 2018 Jun; 96(4):411-419. PubMed ID: 29220112
[TBL] [Abstract][Full Text] [Related]
17. A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab.
Su E; Oza VS; Latkany P
J Formos Med Assoc; 2019 May; 118(5):945-950. PubMed ID: 30616991
[TBL] [Abstract][Full Text] [Related]
18. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
Park UC; Cho IH; Lee EK; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
[TBL] [Abstract][Full Text] [Related]
19. Unilateral Ocular Manifestations of Vogt-Koyanagi-Harada Disease.
Tsui E; Bottini A; Ghadiali Q; Balaratnasingam C; Barbazetto I
Ocul Immunol Inflamm; 2018; 26(8):1297-1300. PubMed ID: 29020488
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
